Agilent Technologies launches AssayMAP Bravo for protein purification

NewsGuard 100/100 Score

Agilent Technologies Inc. today announced the launch of the AssayMAP Bravo platform and protein purification cartridges, a fully automated solution for high-throughput protein sample preparation and purification.

Combining the best-in-class liquid handling of the Agilent Bravo with the AssayMAP Protein A micro-chromatography technology, the Bravo for Protein Purification enables quick, precise and highly parallel microscale purification of target antibodies. With this combined solution, customers can generate high-purity samples that can be used for direct titer assays or downstream characterization and processing applications.

"This launch offers a complete solution for a variety of sample prep applications and saves valuable time developing and validating assays, allowing customers to focus on generating business-critical data to advance their biologics pipeline," said Nitin Sood, general manager of Agilent's Automation Solutions Division. "The AssayMAP Bravo and cartridges for protein purification are ideal for those in biologics discovery and development who need streamlined, precise purification of their protein of interest."

The Bravo for Protein Purification uses disposable, 5-microliter packed-bed AssayMAP cartridges in a 96-channel microplate format, which reduces the amount of starting sample used and speeds time to results. Target protein can be purified from a variety of common sources, including:

  • cell culture supernatants
  • cell culture lysates
  • hybridoma cultures
  • protein expression systems

The AssayMAP Bravo for Protein Purification is a fully supported system, with hardware and software as well as the cartridges used in the equipment available directly from Agilent.

Source: Agilent Technologies Inc

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
An ActRIIA fusion protein got FDA approved for PAH treatment